Skip to main content
TipRanks
Go Ultimate75% OFF

ARS Pharmaceuticals (SPRY) Stock Statistics & Valuation Metrics

593 Followers

Total Valuation

ARS Pharmaceuticals has a market cap or net worth of $391.06M. The enterprise value is $413.10M.

Market Cap
$391.06M
Enterprise Value
$413.10M

Share Statistics

ARS Pharmaceuticals has 100,528,400 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
100,528,400
Owned by Insiders
26.89%
Owned by Institutions
35.57%

Financial Efficiency

ARS Pharmaceuticals’s return on equity (ROE) is -1.50 and return on invested capital (ROIC) is -62.17%.

Return on Equity (ROE)
-1.50
Return on Assets (ROA)
-0.52
Return on Invested Capital (ROIC)
-62.17%
Return on Capital Employed (ROCE)
-0.62
Revenue Per Employee
415.16K
Profits Per Employee
-843.83K
Employee Count
203
Asset Turnover
0.26
Inventory Turnover
2.44

Valuation Ratios

The current PE Ratio of ARS Pharmaceuticals is -1.93. ARS Pharmaceuticals’s PEG ratio is 0.02.

PE Ratio
-1.93
PS Ratio
3.20
PB Ratio
-32.44
Price to FCF
-2.14
Price to Operating Cash Flow
-2.12
PEG Ratio
0.02

Income Statement

In the last 12 months, ARS Pharmaceuticals had revenue of 84.28M and earned -171.30M in profits. Earnings per share was -1.74.

Revenue
84.28M
Gross Profit
63.85M
Operating Income
-179.45M
Pretax Income
-171.38M
Net Income
-171.30M
EBITDA
-167.41M
Earnings Per Share (EPS)
-1.74

Cash Flow

In the last 12 months, operating cash flow was -183.07M and capital expenditures 0, giving a free cash flow of -183.07M billion.

Operating Cash Flow
-183.07M
Free Cash Flow
-183.07M
Free Cash Flow per Share
-1.84

Dividends & Yields

ARS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-46.81%
Earnings Yield
-51.54%

Stock Price Statistics

Beta
1.40
52-Week Price Change
-53.75%
50-Day Moving Average
4.08
200-Day Moving Average
6.99
Relative Strength Index (RSI)
53.06
Average Volume (3m)
1.78M

Important Dates

ARS Pharmaceuticals upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 25, 2027
Ex-Dividend Date
―

Financial Position

ARS Pharmaceuticals as a current ratio of 7.28, with Debt / Equity ratio of 84.35%

Current Ratio
7.28
Quick Ratio
7.06
Debt to Market Cap
0.08
Net Debt to EBITDA
-0.33
Interest Coverage Ratio
-69.05

Taxes

In the past 12 months, ARS Pharmaceuticals has paid -80.00K in taxes.

Income Tax
-80.00K
Effective Tax Rate
0.00

Enterprise Valuation

ARS Pharmaceuticals EV to EBITDA ratio is -2.95, with an EV/FCF ratio of -3.07.

EV to Sales
4.61
EV to EBITDA
-2.95
EV to Free Cash Flow
-3.07
EV to Operating Cash Flow
-3.07

Balance Sheet

ARS Pharmaceuticals has $138.35M in cash and marketable securities with $197.01M in debt, giving a net cash position of -$58.66M billion.

Cash & Marketable Securities
$138.35M
Total Debt
$197.01M
Net Cash
-$58.66M
Net Cash Per Share
-$0.58
Tangible Book Value Per Share
-$0.26

Margins

Gross margin is 73.45%, with operating margin of -161.50%, and net profit margin of -163.64%.

Gross Margin
73.45%
Operating Margin
-161.50%
Pretax Margin
-163.71%
Net Profit Margin
-163.64%
EBITDA Margin
-156.24%
EBIT Margin
-157.59%

Analyst Forecast

The average price target for ARS Pharmaceuticals is $17.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$17.33
Price Target Upside
345.59% Upside
Analyst Consensus
Strong Buy
Analyst Count
3
Revenue Growth Forecast
-14.45%
EPS Growth Forecast
-148.35%

Scores

Smart Score
2
AI Score
45